Literature DB >> 28064153

Comparison of valve performance of the mechanically expanding Lotus and the balloon-expanded SAPIEN3 transcatheter heart valves: an observational study with independent core laboratory analysis.

Osama I I Soliman1,2, Nahid El Faquir1, Ben Ren1, Ernest Spitzer1,2, Lennart van Gils1, Hans Jonker2, Marcel L Geleijnse1, Gerrit-Anne van Es2, Jan G Tijssen2, Nicolas M van Mieghem1, Peter P T de Jaegere1.   

Abstract

Aims: The Lotus and SAPIEN3 are second-generation transcatheter heart valves, which are designed to minimize paravalvular aortic regurgitation (PAR) after transcatheter aortic valve replacement (TAVR). We sought to compare both devices for valve performance and with emphasis on PAR by independent core laboratory analysis. Methods and results: A total of 162 (79 Lotus and 83 SAPIEN3) consecutive patients (51% female, 80 ± 8 years, Logistic EuroSCORE 14.8 ± 9.4%) who underwent TAVR because of aortic stenosis were included. Patients with aortic valve-in-valve treatment were excluded. Pre-discharge echocardiograms were analysed by an independent core laboratory using the Valve Academic Research Consortium 2 criteria. There were no differences in baseline and procedural characteristics, except for a larger aortic annulus and sizing indices in SAPIEN3-treated patients and frequency of post-dilatation (0% in Lotus and 13.1% in SAPIEN3). Both valves have similar mean residual gradient, indexed effective orifice area and Doppler velocity index when adjusted to valve size. The frequency of mild (13.9% vs. 31.3%) and at least moderate (1.3% vs. 3.6%) PAR was less after Lotus than after SAPIEN3 implantation (P = 0.02). Multi-slice computed tomography-based annulus and left ventricular outflow tract diameters, calcification and percentage of oversizing were not different between those with or without mild or more PAR. On multivariate analysis, the use of Lotus valve was associated with less (odds ratio OR, 0.41, P = 0.03) occurrence of PAR.
Conclusion: Overall, haemodynamic performance was comparable between the Lotus and SAPIEN3 valves. Lotus valve required less oversizing and was associated with less PAR than SAPIEN3. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  TAVR; aortic; echocardiography; haemodynamic; outcome; regurgitation; stenosis; valve

Mesh:

Year:  2018        PMID: 28064153     DOI: 10.1093/ehjci/jew280

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  4 in total

1.  Head to head transcatheter heart valve comparisons: when theory becomes reality.

Authors:  Gabriela Tirado-Conte; German Armijo; Luis Nombela-Franco
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

2.  Editorial comment on the RESPOND study.

Authors:  Daniel Wendt; Matthias Thielmann; Sharaf Eldin Shehada; Konstantinos Tsagakis; Heinz Jakob; Mohamed El Gabry
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

3.  The Role of Quantitative Aortographic Assessment of Aortic Regurgitation by Videodensitometry in the Guidance of Transcatheter Aortic Valve Implantation.

Authors:  Yosuke Miyazaki; Rodrigo Modolo; Mohammad Abdelghani; Hiroki Tateishi; Rafael Cavalcante; Carlos Collet; Taku Asano; Yuki Katagiri; Erhan Tenekecioglu; Rogério Sarmento-Leite; José A Mangione; Alexandre Abizaid; Osama I I Soliman; Yoshinobu Onuma; Patrick W Serruys; Pedro A Lemos; Fabio S de Brito
Journal:  Arq Bras Cardiol       Date:  2018-08       Impact factor: 2.000

4.  Transcatheter aortic valve replacement with Lotus and Sapien 3 prosthetic valves: a systematic review and meta-analysis.

Authors:  Mirosław Gozdek; Jakub Ratajczak; Adam Arndt; Kamil Zieliński; Michał Pasierski; Matteo Matteucci; Dario Fina; Federica Jiritano; Paolo Meani; Giuseppe Maria Raffa; Pietro Giorgio Malvindi; Michele Pilato; Domenico Paparella; Artur Słomka; Uri Landes; Ran Kornowski; Jacek Kubica; Roberto Lorusso; Piotr Suwalski; Mariusz Kowalewski
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.